PET/CT & Nuclear Medicine Facility Shielding (AAPM TG-108)
Key Takeaways
AAPM TG-108 recommends a dose-rate constant of 0.143 µSv·m²/(MBq·h) for F-18 (effective dose equivalent basis) and 0.092 µSv·m²/(MBq·h) for a patient immediately after injection, a body absorption of about 36%.
Because F-18 decays during the uptake and imaging periods, TG-108 multiplies by a reduction factor R_t = 1.443 (T½/t)[1 − exp(−0.693 t/T½)], which is 0.91, 0.83, and 0.76 for 30, 60, and 90 minutes.
For an uptake room the required transmission to an uncontrolled area is B = 218·d²/(T·N·A₀·t_U·R_tU), with d in metres, A₀ in MBq, t_U in hours, and a weekly design goal of 20 µSv (100 µSv for controlled areas).
Narrow-beam HVLs at 511 keV (4.1 mm lead, 3.4 cm concrete) underestimate the shielding needed, so TG-108 uses Monte Carlo broad-beam transmission data; for example, 10 mm of lead transmits about 25% and 20 mm about 5%.
Before imaging, decay during uptake (0.68 after 60 minutes) and voiding (a factor of 0.85) reduce the patient's activity; the CT component of a PET/CT is shielded with NCRP 147 methods and its contribution is added.
PET/CT & Nuclear Medicine Facility Shielding (AAPM TG-108)
Positron emission tomography brings a shielding problem that ordinary nuclear medicine does not: every positron annihilation releases two 511 keV photons, far more penetrating than the 140 keV photons of technetium-99m. The patient is also a moving source, injected in one room, resting in an uptake room, imaged in another, and sometimes held in a recovery area. AAPM Task Group 108 (PET and PET/CT Shielding Requirements, Medical Physics 2006) gives the methods most US physicists use, and its numbers come up on board examinations.
Source Terms: Point Source versus Patient
The most common PET agent, -FDG, has a physical half-life of about . TG-108 reviewed the published "dose-rate constants" for F-18, which range from about (air kerma rate constant) to (an older maximum-dose value), and recommends the effective-dose-equivalent value because regulatory limits are written in effective dose:
| Quantity (TG-108) | Value |
|---|---|
| F-18 dose-rate constant, unshielded point source | (about ) |
| F-18 dose-rate constant for a patient, right after injection | |
| Implied body absorption | about () |
| Other PET nuclides (point source) | C-11, N-13, O-15: ; Ga-68: ; Rb-82: ; I-124: |
The patient value is the mean of published measurements around patients, corrected back to the time of administration.
Decay During Occupancy
Because the activity decays while the patient sits in a room, TG-108 replaces the initial dose rate times the time with the initial dose rate times the time times a reduction factor:
For F-18, , , and for , , and .
Uptake-Room Equation
With patients per week, administered activity (MBq), uptake time (h), and distance (m), the weekly dose at the protected point is (in µSv). Setting this equal to gives the required transmission:
With the US design goals of per week for uncontrolled areas and per week for controlled areas, the constant becomes 218 and 1,090. TG-108's own example (40 patients per week, , uptake, an uncontrolled fully occupied point away) needs , met by about of lead or of concrete.
Imaging-Room Equation
By the time the patient reaches the scanner the activity has decayed by (0.68 after a 60-minute uptake), and voiding removes roughly 15% of the activity, so TG-108 multiplies by 0.85. The constant becomes 256 (uncontrolled) or 1,280 (controlled), and and for the imaging time replace the uptake values. The gantry itself shields some walls, and TG-108 notes that for a five-bed-position scan the scanner conservatively reduces the dose by about 20%; manufacturer data can be used where available.
Transmission at 511 keV
Narrow-beam ("good geometry") values give an HVL of of lead and of concrete, but calculations with these values underestimate the shielding needed because they ignore scatter buildup. TG-108 instead provides Monte Carlo broad-beam transmission factors:
| Thickness | Lead (mm) | Concrete (cm) | Iron (cm) |
|---|---|---|---|
| 5 | 0.523 | 0.722 | 0.148 |
| 10 | 0.249 | 0.399 | 0.0107 |
| 20 | 0.0535 | 0.0904 | below 0.0001 |
| 30 | 0.0114 | 0.0194 | |
| 50 | 0.0005 | 0.0009 |
Thickness in the first column is millimetres for lead and centimetres for concrete (density ) and iron.
Worked Example: Uptake Room Next to an Office
An uptake room handles patients per week, each given of -FDG and resting (). A fully occupied office (uncontrolled, ) lies from the patient chair.
From the TG-108 lead data, transmits and transmits , so about of lead is needed (about of concrete would also work). A -inch () sheet falls just short, so the designer would specify -inch () lead or verify the existing wall's concrete. Without the reduction factor, or using narrow-beam HVLs, the answer would be wrong in opposite directions, which is why each step matters.
PET/CT and the Rest of the Department
- Add the CT: The CT of a PET/CT is shielded with the NCRP 147 dose-length-product method, and its secondary air kerma is added to the PET contribution at each point. Lead sized for 511 keV usually covers the CT scatter as well, but the sum must still meet the design goal.
- Other rooms: Hot labs, dose-calibrator areas, injection rooms, patient toilets, and recovery bays are all sources; a single wall may receive contributions from several rooms.
- Floors and ceilings: Concrete slabs attenuate 511 keV photons much less than diagnostic x-rays, so rooms above and below uptake rooms need explicit calculation.
Pitfall
- Using the point-source constant for patients, or omitting decay: Using instead of around patients and ignoring overestimates the dose, while using narrow-beam HVLs underestimates the lead; TG-108 corrects both errors.
Under AAPM Task Group 108, what dose-rate constant is used for an F-18 FDG patient immediately after injection, and what does it imply about the patient's body?
0.143 µSv·m²/(MBq·h), because 511 keV photons pass through the body without measurable attenuation.
0.015 µSv·m²/(MBq·h), because about 90% of injected FDG is exhaled through the lungs within the first few minutes.
0.188 µSv·m²/(MBq·h), because backscatter within the patient's body increases the dose rate above the point-source value.
0.092 µSv·m²/(MBq·h), about 64% of the 0.143 point-source value, implying roughly 36% absorption in the body.
A PET uptake room serves 25 patients per week, each given 370 MBq of F-18 FDG with a 1-hour uptake (R_t = 0.83). Using the TG-108 uptake-room equation, what transmission is required at a fully occupied office (uncontrolled, T = 1) 3.0 m from the patient chair?
About 0.085
About 0.256
About 0.026
About 1.28, so no shielding is needed
Why does AAPM Task Group 108 tell designers not to calculate PET barriers from the narrow-beam half-value layers of 4.1 mm lead and 3.4 cm concrete?
Because the NRC requires PET rooms to be designed with the NCRP 151 megavoltage TVLs used for linear accelerator vaults.
Narrow-beam values ignore buildup of scattered photons in a real barrier, so they underestimate the shielding; TG-108 gives broad-beam data.
Because 511 keV photons undergo pair production in lead, which makes narrow-beam HVLs overestimate the thickness that is actually needed.
Because PET photons are emitted at 140 keV, so the 511 keV values do not apply.
Sections you finish are checked off in the contents.